touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) discusses his recent phase II study exploring the benefits, efficacy and safety of tyrosine kinase inhibitors dasatinib–blinatumomab for the treatment of Ph-positive acute lymphoblastic leukemia in adults.
- What is the rationale for the use of dasatinib plus glucocorticoids, followed by blinatumomab, rather than chemotherapy, in the treatment of adults with newly diagnosed? Ph+ acute lymphoblastic leukemia? 00:12-02:30
- Could you give us a brief overview of the Phase II study investigating this regimen? 02:30-04:14
- What were the efficacy, safety and tolerability findings of the study? 04:14-07:02
- Which patients are most likely to benefit from this regimen? 07:02-08:39
- What questions remain unanswered and what future studies are planned? 08:39-11:43
- Please summarise the findings from the ancillary studies? 11:43-13:42
- Please discuss the importance of laboratory testing, home treatment and the benefits of this approach during the COVID-19 pandemic 13:42-16:13
Speaker Disclosure: Robin Foà has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Share this Video
Related Videos In Leukaemia
Michael Mauro, ASH 2021: 48-Week Update of the Phase III ASCEMBL Trial
Professor Michael Mauro (Memorial Sloan Kettering Cancer Center, New York City, NY, USA) discusses the 48-week update from the ASCEMBL trial, a multicenter, open-label, phase III study of the efficacy and safety of asciminib, a first-in-class STAMP inhibitor, vs Bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: […]
Robin Foà: Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) discusses his recent phase II study exploring the benefits, efficacy and safety of tyrosine kinase inhibitors dasatinib–blinatumomab for the treatment of Ph-positive acute lymphoblastic leukemia in adults. Questions What is the rationale for the use of dasatinib plus glucocorticoids, followed by blinatumomab, rather […]
Elias Jabbour, ASH 2021: Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (PACE and OPTIC Trials)
We were delighted to catch up with editorial board member Prof Elias Jabbour (MD Anderson Cancer Center, Houston, TX, USA) to discuss his presentation at the American Society of Hematology (ASH) Annual Meeting on dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia from the PACE and Optic trials. Questions 1. What […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!